ASCO Connection

September 2017

Issue link: http://read.uberflip.com/i/869954

Contents of this Issue

Navigation

Page 2 of 67

ASTRA learn more ©2017 AstraZeneca. All rights reserved. US-9509 6/17 *Based on 194 patients treated with concurrent CRT. References: 1. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer. Lancet. 2009;374:379-386. 2. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIb non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006;8:116-121. Although many patients may initially benefit from chemoradiation therapy (CRT), there is a significant unmet need for improved treatment outcomes in locally advanced NSCLC following CRT 1,2 • The median progression-free survival is <12 months after CRT completion* 1 • Median OS after CRT is less than 2 years* 1 AstraZeneca is evaluating the role of immunotherapy in locally advanced NSCLC following CRT

Articles in this issue

Archives of this issue

view archives of ASCO Connection - September 2017